23andMe Holding Co - Class A

-$0.04 (-6.9%)
Closing price May 20, 2024

ME Chart and Intraday Price

ME Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Fiscal Year End March
Latest Quarter 12/31/2023
Market Cap 262.85M USD
Shares Outstanding 315,436,000
23andMe Holding Co. is a pioneer in consumer genetics testing, offering insights into genetic ancestry, health risks, and how DNA affects medication responses. Beyond personal genetics, it operates Lemonaid telehealth for easy access to medical consultations. In the realm of drug development, 23andMe is actively working on novel therapies in areas like oncology and cardiovascular diseases, aiming to transform patient care. Its innovative approach includes developing drugs that leverage genetic insights, such as a monoclonal antibody in clinical trials for cancer treatment.

ME Articles

23andMe shares have been driven down to penny stock levels, and its CEO wants to take the company private before it runs out of money.
23andMe stock has collapsed in the past year, as the company has come under attack by investors and the media.
Meme stocks as a group traded lower Monday and were not seeing much action in Tuesday's premarket session.
Monday's top analyst upgrades and downgrades included Akamai Technologies, ChargePoint, Chevron, Costco Wholesale, Dollar Tree, Kimberly-Clark, Plains All American Pipeline and Shopify.
Here are previews of four companies reporting quarterly results after markets close Tuesday or before they open Wednesday morning.
Space tourism company Virgin Galactic is having a tough day Friday while DNA testing firm 23andMe is having a good one.
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. They are not penny stocks with no track record or liquidity, and...
Tuesday's top analyst upgrades and downgrades included Allstate, ADP, Baker Hughes, Coupa Software, Hyatt Hotels, Lemonade, Robinhood Markets and Suncor Energy.
24/7 Wall St. takes a look at famed market personality Jim Cramer’s latest buy and sell recommendations and overall analysis.